93 related articles for article (PubMed ID: 15488948)
1. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg.
Iglesias E; Aguilar JC; Cruz LJ; Reyes O
Mol Immunol; 2005 Jan; 42(1):99-104. PubMed ID: 15488948
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins.
Cruz LJ; Cabrales A; Iglesias E; Aguilar JC; González LJ; Reyes O
Int Immunopharmacol; 2009 Nov; 9(12):1452-9. PubMed ID: 19747570
[TBL] [Abstract][Full Text] [Related]
3. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of different presentation strategies for an HIV peptide immunogen.
Cruz LJ; Iglesias E; Aguilar JC; González LJ; Reyes O; Albericio F; Andreu D
Bioconjug Chem; 2004; 15(1):112-20. PubMed ID: 14733590
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
8. A receptor mediated delivery of an HIV-1 derived peptide vaccine.
Mitsuda S; Nakagawa T; Osada T; Shimamoto T; Nakazato H; Ikai A
Biochem Biophys Res Commun; 1993 Aug; 194(3):1155-60. PubMed ID: 7688961
[TBL] [Abstract][Full Text] [Related]
9. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120.
Berkower I; Raymond M; Muller J; Spadaccini A; Aberdeen A
Virology; 2004 Mar; 321(1):75-86. PubMed ID: 15033567
[TBL] [Abstract][Full Text] [Related]
10. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S
Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228
[TBL] [Abstract][Full Text] [Related]
11. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
[TBL] [Abstract][Full Text] [Related]
13. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.
Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX
Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
[TBL] [Abstract][Full Text] [Related]
15. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
16. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
17. Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity.
Lamalle-Bernard D; Munier S; Compagnon C; Charles MH; Kalyanaraman VS; Delair T; Verrier B; Ataman-Onal Y
J Control Release; 2006 Sep; 115(1):57-67. PubMed ID: 16919350
[TBL] [Abstract][Full Text] [Related]
18. [Vaccination with three HIV-1 cross neutralizing epitopes fused to HBV S antigen could induce robust antibody immune response in mice].
Li XR; Chen H; Wang W; Deng Y; Qi XR; Gao YY; Meng X; Tan WJ; Ruan L
Bing Du Xue Bao; 2008 Jul; 24(4):260-7. PubMed ID: 18780627
[TBL] [Abstract][Full Text] [Related]
19. Improving on nature: focusing the immune response on the V3 loop.
Zolla-Pazner S
Hum Antibodies; 2005; 14(3-4):69-72. PubMed ID: 16720976
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study of candidate vaccines against variable or quasi-species pathogenes: multiepitopic synthetic peptide antigenes and new receptor-guiding adjuvants].
Ignat'eva GA; Maksiutov AZ; L'vov VL; Kolobov AA; Ignat'ev TI
Patol Fiziol Eksp Ter; 2011; (3):40-2. PubMed ID: 22279739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
